A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for ...

The FDA has granted Fast Track designation to the investigational antibody-drug conjugate (ADC) SIM0505 for the treatment of women with platinum-resistant ovarian cancer. The designation adds SIM0505 ...

Adding relacorilant to nab-paclitaxel improved median OS by 4 months ...

Dr. Alexander B. Olawaiye presented findings at the 2026 Society of Gynecologic Oncology Annual Meeting showing that adding ...

Dr Robert Coleman, chief scientific officer of the US Oncology Network, reflects on the evolution of ovarian cancer treatment guidelines from early in his career to the dramatic shifts in the past few ...

Fred Hutch at AACR: Colorectal cancer and glyphosate exposure, potential therapeutic targets for ovarian cancer, a new molecular standard of care for cancer patients — and more ...

A newly identified interaction between ovarian cancer cells and surrounding abdominal cells helps explain the cancer’s ...

PARP Inhibitor Improves Outcomes in Ovarian Cancer In women with relapsed ovarian cancer, maintenance treatment with olaparib significantly improved progression-free survival. Medscape Medical News, ...

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ...

Rising ovarian and uterine cancer rates are linked to high BMI, with disparities across sociodemographic index levels, particularly in low- and middle-SDI regions. Sarcopenia is prevalent in ...

The data, presented during an oral plenary session at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on ...

Cells in our immune system are best known for providing security against external invaders such as bacteria and viruses. These immune cells also guard against internal threats, including cancerous ...